MedTech Entrepreneurs Management

Managing Partner Dominik Moll leads the firm. He draws on two decades of executive roles at Johnson & Johnson, Kimberly-Clark, and 3M, plus 15 years as a c-level shareholder in MedTech SMEs. The firm lists four additional venture partners — Dr. Andreas Lindner, Dr. Jörg Muschiol, Carl Härtlein, and Dr. Franz MJ Pfister — who contribute deal-sourcing, clinical, and operational expertise, but ultimate investment authority rests with the managing partner and the investment committee.

MTE sources predominantly from academically rooted MedTech founders across Germany, Austria, and Switzerland, leveraging the managing partner's management-due-diligence background and the venture partners' hospital and clinical-trial networks. The firm deploys a 'cooperative milestone management' model that embeds operating partners into corporate governance and reimbursement strategy early, which attracts founders needing regulatory pathway support before larger VCs engage.

MedTech Entrepreneurs Management is structured as an asset manager raising a dedicated venture fund — a GmbH registered in Graefelfing, Germany. It is not a single family office; it operates as an independent fund manager targeting external limited partners for its €50 million early-stage MedTech and Digital Health vehicle.

MTE makes direct early-stage equity investments into medical-device and digital-health startups, with initial tickets from €500,000 to €3 million. It does not publish information about participating in other fund commitments as a limited partner.

The firm explicitly targets pre-seed and early-stage rounds, characterizing itself as a bridge between angel investors and larger venture-capital funds. It enters before syndicates are fully formed, often as the first institutional check, and works with founders to achieve milestones that de-risk later-stage investment.

The firm states clearly on its website that it does not invest in pharmaceutical or biotechnology companies. Its mandate covers medical devices (Class I through III), Digital Health Applications (DiGA), and hygiene and infection-prevention technologies but excludes drug development and biotech platforms.

MTE treats prospective NUB/DRG/DiGAV reimbursement status as a central investment criterion. The firm cites data showing 97% of startups fail to secure new reimbursement codes in Germany and incorporates reimbursement-application planning into its milestone-based operational support for portfolio companies, using this as both a risk-mitigation lever and a value-creation thesis.